Coagulase-negative Staphylococcus (CoNS) is the most common cause of acute-onset post-cataract surgery endophthalmitis.
Results | In this study of coagulase-negative Staphylococcus from patients with endophthalmitis, susceptibility rates among fluoroquinolones (ciprofloxacin, levofloxacin, and moxifloxacin) were reviewed between January 1, 1995, and December 31, 2016 (Figure) .
Ciprofloxacin | The nonsusceptibility rates for ciprofloxacin were 28% (n = 83) from 1995 to 1999, 59% (n = 63) from 2000 to 2004, 63% (n = 75) from 2005 to 2009, and 56% (n = 97) from 2010 to 2016. The nonsusceptibility to ciprofloxacin increased from 28% between 1995 28% between and 1999 28% between to 56% between 2010 28% between and 2016 ; P < .001).
Levofloxacin | The nonsusceptibility rates for levofloxacin were 17% (n = 23) from 1995 to 1999, 52% (n = 56) from 2000 to 2004, 61% (n = 71) from 2005 to 2009, and 56% (n = 97) from 2010 to 2016. The nonsusceptibility to levofloxacin increased from 17% between 1995 17% between and 1999 17% between to 56% between 2010 17% between and 2016 , P < .001).
Moxifloxacin | The nonsusceptibility rates for moxifloxacin were 22% (n = 23) from 1995 to 1999, 23% (n = 26) from 2000 to 2004, 60% (n = 63) from 2005 to 2009, and 57% (n = 97) from 2010 to 2016. The nonsusceptibility to moxifloxacin increased from 22% between 1995 22% between and 1999 22% between to 57% between 2010 22% between and 2016 .65-52.52, P = .003).
Discussion | In this study, the nonsusceptibility of CoNS to all 3 generations of fluoroquinolones increased during the time period of 22 years. In another study, nonsusceptibility to these antibiotics was shown to rapidly occur with repeated exposure of conjunctival Staphylococcus epidermidis to fluoroquinolones or azithromycin.
2 Increase in the resistance among all of conjunctival flora with repeated exposure to topical antibiotics (ofloxacin, 0.3%; azithromycin, 1%; gatifloxacin, 0.3%; or moxifloxacin hydrochloride, 0.5%) has been reported.
2,3
Similarly, in a prospective study, CoNS resistant to fluoroquinolones were also reported to have resistance to multiple other antibiotics. Endophthalmitis caused by CoNS nonsusceptible to fluoroquinolones has been reported to be associated with a poorer visual prognosis.
4
Various studies have advocated the prophylactic use of moxifloxacin (topical or intracameral) to reduce postcataract surgery endophthalmitis rates.
5 Although endophthalmitis prophylaxis with intracameral antibiotics is commonly used in Europe, this practice is less consistently used in the United States. However, these studies do not constitute level I evidence, and thus, there is no worldwide consensus regarding endophthalmitis prophylaxis with cataract surgery.
6
Limitations. This study is limited by its retrospective nature and the possibility of selection bias. The mechanism of this increasing nonsusceptibility to fluoroquinolones is not fully understood, but it may be associated with widespread use of fluoroquinolones, use of antibiotics outside of the health care sector, and emergence of intrinsic genetic factors promoting resistance. Although this study involves only in vitro testing, the clinical implications of this laboratory data requires further investigations. Melphalan is a well-established alkylating agent, developed in 1953 and used to treat several hematologic malignancies, including lymphoma, leukemia, and multiple myeloma, as well as solid tumors including breast, ovarian, and neural cancers.
5 When used in the vitreous for retinoblastoma, filtered preparation of 20 μg/0.1 mL is sufficient for tumor control. 6 Owing to its effect on lymphoma and our experience with this medication, we challenged PVRL with melphalan.
Methods | This retrospective investigation was approved by the institutional review board of Wills Eye Hospital. Three eyes of 2 patients with biopsy-confirmed PVRL were offered standard treatment or intravitreal melphalan (low dose [10 μg/0.1 mL]). Following written consent, the medication was injected into the vitreous using sterile technique. Clinical features and outcomes were recorded.
Results | Case 1. A 92-year-old woman with vitrectomy-proven bilateral PVRL (large B-cell lymphoma cytology) demonstrated severe vitreous tumor infiltration in the right eye and mild infiltration in the left eye, with subretinal pigment epithelial tumor in the left eye (Figure 1) . Visual acuity was 20/30 OD and 20/40 OS. She was treated with low-dose intravitreal melphalan (10 μg/0.1 mL) to both eyes. Following initial injection, complete clearance of vitreous tumor in both eyes was noted within 3 weeks. During the 19-month followup, the right eye required 6 bimonthly injections for minor seed recurrence, and the left eye remained stable without recurrence. There were no toxicities in either eye, but the left eye showed stable focal subfoveal fluid, with mild macular edema at presentation and throughout her course. Final visual acuity was 20/50 OU.
